We have analysed the relationship of the products of two genes, neu and BRCA1, known to be important in human breast cancer. Highly speci®c antibodies that recognized both the rodent and human form of the BRCA1 gene product (M r 215 kDa, p215 BRCA1 ) were developed to facilitate these eorts. p215
Introduction
BRCA1, a breast and ovarian cancer susceptibility gene, has been localized to chromosome 17q21 by linkage analysis (Hall et al., 1990) and identi®ed by positional cloning (Miki et al., 1994) . Structural defects in this gene account for a signi®cant percentage of inherited early onset breast cancer (Easton et al., 1995) but appear less important in sporadic tumors. Nevertheless, BRCA1 may exert an indirect eect on the regulation of gene expression in sporadic tumors if its function is adversely aected by other dominant oncoproteins. Therefore we examined whether overexpression or constitutive activation of a dominant oncoprotein such as neu might aect the functional state of BRCA1 in a variety of growth contexts.
The cDNA of the BRCA1 gene encodes a protein of 1863 amino acids (Miki et al., 1994) . Although two conserved putative nuclear localization signals and a potential Ring-®nger motif suggest that the BRCA1 protein might be a nuclear protein (Miki et al., 1994; Lane et al., 1995; Thakur et al., 1997) , discrepancies exist concerning BRCA1 subcellular localization. Chen et al. (1995) observed that BRCA1 was a nuclear protein in normal and non-breast/ovarian cancer cells, while in breast/ovarian cancer cells BRCA1 was exclusively localized in the cytoplasm. A suggestion was made that abnormalities of nuclear transport in sporadic tumors might aect BRCA1 cellular localization. However, Scully et al. (1996) reported that BRCA1 was predominantly localized in the nucleus of normal as well as breast/ovarian cancer cells. Recently, a pathway for BRCA1 secretion was also described Jensen et al., 1996) . Possible crossreactions of the antisera used in that study have been raised as a potential problem (Wilson et al., 1996) . The function of the BRCA1 protein and its relation with other signaling or transport proteins therefore remains incomplete.
In the present study we demonstrate that the product of the BRCA1 gene is a nuclear protein and that its phosphotyrosine content is correlated with the transformed phenotype of the cells, as well as some events in the cell cycle. Furthermore we describe that the erbB family of genes can in¯uence the posttranslational modi®cation of p215 BRCA1 indicating that these breast-cancer-related genes share or interact with a common signaling pathway.
Results

Generation and characterization of antibodies against a BRCA1 peptide
To characterize the BRCA1 gene product and its role in transformation, rabbit polyclonal antibodies were generated against a peptide corresponding to the amino acids 903 ± 919 of the human BRCA1 gene product. The antiserum 579 speci®cally recognized the in vitro translated human BRCA1 products ( Figure 1a ) and also the BRCA1 peptide immobilized onto nitrocellulose membranes (not shown). The speci®c antigen ± antibody interaction was blocked by the immunizing BRCA1 peptide (Figure 1a , lane 5). Despite dierences of the sequence in the epitope region between human and murine BRCA1 (Lane et al., 1995; Abel et al., 1995) , the antiserum 579 identi®ed a polypeptide p215 BRCA1 in human and mouse cell lines (Figure 1b ), indicating that the BRCA1 peptide likely exhibits some structural features shared between the intact rodent and human BRCA1 polypeptides. The polypeptide immunoprecipitated by 579 could be recognized by the commercially available polyclonal antibody M-20 (Santa Cruz, Inc.) that was generated against a Cterminal peptide of mouse BRCA1 (Figure 1c) . Consistent with the polyclonal antiserum 579 data, a monoclonal antibody Ki.8, raised against the same peptide could also identify both human and mouse forms of p215 BRCA1 and immunoblot analysis with multiple antibodies con®rmed the identity of p215 BRCA1 ( Figure 1d ). As seen in Figure 1d , the polypeptide precipitated by Ki.8 was also recognized by another panel of widely used anti-BRCA1 antibodies: the polyclonal antibody C20 (Santa Cruz, Inc.) which was raised against the C-terminal region of human BRCA1; and the monoclonal antibody Ab-1 (Oncogene Science, Inc.) that was generated against the N-terminal region of BRCA1, as well as 579. In other studies, human BRCA1 polypeptides of 220 kDa (Chen et al., 1995; Scully et al., 1996) , , and the murine cell line B104-1-1 (as indicated) were prepared as described (Sadowski et al., 1993) and separated on SDS-polyacrylamide gels (50 mg proteins per lane), then immunoblotted with the antiserum 579 (lanes 3 ± 8) or the preimmune serum (lanes 1 and 2). (c) Proteins from NE91 cell lysates were immunoprecipitated by the pre-immune (PI) rabbit serum (lanes 1 and 3) or the antiserum 579 (lanes 2 and 4) as described (Wada et al., 1990) , separated by SDS-polyacrylamide gels, immunoblotted by the anti-pTyr monoclonal antibody pY20 (lanes 3 and 4) or the anti-BRCA1 polyclonal antibody M20 (lanes 1 and 2), and visualized by ECL. (d) Lysates from human cell lines, U87MG and HBL100 as indicated, and murine NR6 cells were immunoprecipitated by the monoclonal Ki.8 and immunoblotted by pY20 (lanes 1 and 5) , the monoclonal anti-BRCA1 antibody Ab-1 (lanes 2 and 6), the antiserum 579 (lanes 3 and 7) , or the polyclonal anti-BRCA1 antibody C20 (lane 4). Molecular size standards are indicated in kDa. The arrow indicates BRCA1 polypeptide p215 195 kDa , or other molecular weights (Rao et al., 1996) have been identi®ed using other antisera or monoclonal antibodies. The molecular weight of the p215 BRCA1 polypeptide in our studies is comparable to the 220 kDa polypeptide form. In addition to p215 BRCA1 , smaller polypeptide bands were also noted in our experiments (Figure 1d ). Whether these bands are the products of alternative splicing or post-transcriptional modi®cations is now under investigation.
Subcellular localization of the p215 BRCA1 polypeptide
To examine the subcellular localization of BRCA1 in some breast cancer cell lines, we fractionated cells into nuclear and cytosolic extracts (Sadowski et al., 1993) and used the 579 antiserum to identify BRCA1 polypeptides. In the human breast cancer cell lines (SKBR3 and MCF7: Figure 1b ; and T47D: data not shown), one human breast cell line HBL100 (not shown) and one human glioblastoma cell line (U87MG, Figure 2c ) that we examined, the antiserum 579 recognized a nuclear protein with a molecular mass of about 215 kDa. We always noted a weaker band in the cytosol but the major staining was seen in the nuclear preparations. In these studies, nonspeci®c low molecular bands were detected with 579 as well as with the preimmune serum (not shown). This property limited the use of the 579 antiserum to immunoprecipitation and Western blotting and precluded its use in detailed immuno¯uorescence studies. The monoclonal antibody Ki.8 is now being used to evaluate a large panel of human tumors for detailed analysis of cytosolic versus nuclear localization and preliminary studies have veri®ed that some breast cancer cell lines do express immunoactive BRCA1 polypeptides predominantly in the nucleus (Kajino et al., unpublished).
p215
BRCA1 is a tyrosine-phosphorylated protein and the phosphorylation level is inversely related to the transforming potential
The phosphorylation status of speci®c domains of various proteins often correlates with many aspects of cell growth and transformation (reviewed by Hunter, 1995) . We therefore examined BRCA1 tyrosine phosphorylation levels (pTyr) in relation to changes in cell growth and transforming potential. An antiphosphotyrosine (anti-pTyr) monoclonal antibody pY20 was employed in Western blot studies and veri®ed that the p215 BRCA1 immunoprecipitated by 579 was phosphorylated on tyrosine residue(s) (Figure 1c ). The same polypeptide immunoprecipitated by the monoclonal antibody Ki.8 was also tyrosine-phosphorylated ( Figure 1d ). Therefore, we chose to examine whether established signaling pathways known to play a role in breast cancer (Jardines et al., 1993) correlate with changes of phosphorylation of BRCA1. p185 neu is the constitutively activated tyrosine kinase encoded by the rat neu oncogene. Its human homologue, the erbB2 gene, is abnormally expressed in about 30% of sporadic human breast cancers (Jardines et al., 1993) . p185 c-neu assembles into an active receptor complex by forming homodimeric ensembles (p185-p185) or heterodimers with the epidermal growth factor receptor (p185-EGFr) (Dougall et al., 1994) . This family of receptor tyrosine kinases contributes to the transformed phenotype when Tyrosine phosphorylation of BRCA1 correlates with the p185 neu activity and proliferation rate of the cell lines. Equal amounts (50 mg per lane) of nuclear (N) or cytoplasmic (C) proteins from dierent cell lines as indicated were separated by 6% SDS ± PAGE. p215 BRCA1 was visualized by immunoblotting with the polyclonal antibody 579, while tyrosine-phosphorylated proteins were revealed by immunoblotting with the anti-pTyr mAb pY20. Nitrocellulose membranes blotted by pY20 can also be stripped and reprobed with 579 to con®rm the BRCA1 protein level. The densities of ECL protein bands were determined by densitometry scanning. In separate studies we normalized the pTyr density to the protein density of p215. The tyrosine phosphorylation level was expressed as compared to B104-1-1 cells for B104-1-1, B104/T691 and NIH3T3 cells (1 : 1.8 : 3.2), or to U87MG cells for U87MG and U87/T691 cells (1 : 1.5). By all criteria p215 BRCA1 was hypophosphorylated in transformed proliferating B104-1-1 cells compared to NIH3T3 cells. Tyrosine phosphorylation levels presented in this paper are derived from at least two independent experiments cells express oncogenic forms of p185 neu , very high levels of p185 c-neu , or slightly elevated levels of p185 c-neuEGFr heteromers (Dougall et al., 1994) . However, the p185-mediated phenotype can be reversed in a transnegative manner by transfecting the cells with a truncated p185 form (designated T691stop) which lacks much of its endodomain. This p185T691stop mutant disables the tyrosine kinase activity of p185 and EGFr receptor assemblies and causes a phenotypic reversion of malignant cells (Qian et al., 1996) .
We examined p215 BRCA1 pTyr content in oncogenicneu-transformed murine cells (B104-1-1) , in neutransformed murine cells that expressed the p185 kinase de®cient form T691stop and hence possessed a more normal phenotype (B104/T691) (Qian et al., 1996) , and in non-transfected parental cells (NIH3T3) as controls. Cytoplasmic and nuclear protein preparations were probed with 579 and anti-pTyr mAb pY20 (Figure 2a ). Separately we compared tyrosine phosphorylation levels that were also normalized for the actual p215 BRCA1 amount found in each cell line (not shown). By all of these criteria we found that p215 BRCA1 was tyrosine hypophosphorylated in transformed B104-1-1 cells compared with p215
BRCA1 phosphotyrosine content seen in non-transformed NIH3T3 parental cells (Figure 2a) . The pTyr content of p215 BRCA1 in the B104/ T691stop cell line, which exhibited a reduced proliferation rate was intermediate compared to those for the B104-1-1 and NIH3T3 cell lines. As a result of the constitutive kinase activity of p185 neu , B104-1-1 -derived cells appeared to have more tyrosine-phosphorylated bands (Figure 2a, pY20 blot) . Some of these bands migrated very close to the p215 band. However, these are not related to BRCA1 since 579 could not interact with them (Figure 2a, 579 blot) .
We also observed a similar pattern of p215 BRCA1 pTyr levels in cells derived from another ®broblast line, NR6. The lowest pTyr level in Tneu cells (NR6 cells transfected with oncogenic neu cDNA and which overexpress the p185 neu oncoprotein); an intermediate level in Tneu/T691 cells (Tneu-transfected and which also overexpress the truncated T691stop form of neu, Qian et al., 1996) ; and the highest level in the nontransformed NR6 parental cells were noted ( Figure  2b) .
The pTyr levels of the p215 BRCA1 were also found to be increased in U87MG human glioblastoma cells transfected with the T691stop kinase-de®cient neu mutant (U87/T691) compared to U87MG alone (Figure 2c ). Results were also separately con®rmed using scanning densitometry. In U87MG cells, the EGFr is overexpressed and appears to mediate the transformed phenotype (Libermann et al., 1985; Nishikawa et al., 1994) . In U87/T691 cells, the T691stop mutant proteins heterodimerize with the EGF receptor, suppressing transformation characteristics of these tumor cells (O'Rourke et al., 1997). These studies suggest that post-translational modification of p215 BRCA1 can also be in¯uenced by EGFr, another member of the erbB receptor-tyrosine-kinase family, that, at this point includes EGFr, p185 neu and the erbB3 and erbB4 proteins.
The relationship between EGFr and pTyr status of p215 BRCA1 in non-transformed cells which could be induced to proliferate was then examined in NE91 cells. NE91 are NR6 ®broblasts transfected with normal human EGFr. p215 BRCA1 protein levels were generally comparable in cells (starved and unstarved, treated and untreated with EGF after starvation) and remained disposed in the nucleus. However, increased p215 BRCA1 tyrosine phosphorylation was observed in quiescent NE91 cells and reduced p215 BRCA1 tyrosine phosphorylation was found in cells stimulated into proliferation by EGF after serum starvation and growth arrest (Figure 3 ). Collectively these experiments linked hypophosphorylation patterns of p215 BRCA1 with cellular proliferation and hyperphosphorylation with quiescence.
Examination of p215
BRCA1 phosphotyrosine content changes during the cell cycle To investigate if the pTyr content of p215 BRCA1 was cellcycle dependent, NIH3T3 cells were arrested at the G 1 /S phase with aphidicolin and at the G 2 /M phase with nocodazole (Rani et al., 1995; Kiyokawa et al., 1995) . Compared to normal cycling cells, the pTyr content of p215 BRCA1 was unchanged at the G 1 /S transition, but was higher at the G 2 /M transition ( Figure 4 ). However in transformed B104-1-1 cells, we did not observe increased phosphotyrosine levels of p215 BRCA1 at the G 2 /M phase (data not shown). This suggests that normal pTyr post-transitional modification of p215 BRCA1 may be reduced in some erbB transformed cells (Figure 2a) . Interestingly, the protooncogenic p185 c-neu , found in DHFR/G8 cells, is known to have decreased kinase activity during G 2 /M whereas the kinase activity of the oncogenic p185 neu in B104-1-1 cells is not discernibly down-regulated at this stage of the cell cycle (Kiyokawa et al., 1995) . Thus, decreased p185 c-neu/erbB2 activity at certain stages of the cell cycle in non-transformed cells correlates with the increase of the phosphotyrosine content of p215 BRCA1 polypeptides and the decrease of pTyr of p215 BRCA1 observed in transformed cells is caused by the abnormal kinase activity of p185 neu that occurs upstream of p215 BRCA1 and persists through G 2 -M. Figure 3 The tyrosine phosphorylation levels of BRCA1 are inversely parallel with the proliferation of the cell. NE91 cells were cultured in 10% FBS DMEM medium (lane 1) or starved in serum free medium (lanes 2 and 3) for 48 h. Nuclear extracts were prepared directly (lanes 1 and 2) or after stimulation with EGF (1 ng/ml) for 10 min (lane 3). Equal amount of nuclear protein preparations were used for straight Western analysis. Tyrosinephosphorylated proteins were detected by the anti-pTyr mAb pY20. The arrow indicates p215 BRCA1 . Same membrane was stripped and then blotted by 579 to con®rm the comparable p215 BRCA1 amount (not shown)
Discussion
De®nition of pathways that contribute to transformation of human breast and ovarian tissues remains incomplete. We have made polyclonal and monoclonal antibodies against a BRCA1 peptide and found p215 BRCA1 to be a predominantly nuclear protein that can be phosphorylated on tyrosine residues. We examined whether the activity of erbB family of receptor tyrosine kinases was related to the phosphotyrosine content of the BRCA1 gene product. Our data demonstrated a correlation between p185 neu and EGF receptor-mediated cell proliferation and transformation with tyrosine phosphorylation levels of the BRCA1 gene product p215
BRCA1
. The hyperphosphorylated p215 BRCA1 species seen in quiescent NE91 cells ( Figure  3 ) and in the NIH3T3 cells arrested at the G 2 /M checkpoint (Figure 4) indicate that the tyrosinehyperphosphorylated p215 BRCA1 form is associated with the inhibition of cell proliferation and may re¯ect the normal functional state of BRCA1. Conversely, the reduced p215 BRCA1 tyrosine phosphorylation levels seen in the murine B104-1-1 transformed cells and human U87MG glioblastoma cell lines correlates with unrestricted cell-cycle progression, proliferation and transformation. Furthermore, our studies illustrate a feature of transformation in which a dominant oncogene (neu) can recruit other downstream proteins, such as p215 BRCA1 , which may then contribute to the transformed phenotype. Such chronic and constitutive activation of erbB family of receptor tyrosine kinases results in a functional state of the p215 BRCA1 protein as if it were mutated.
Several lines of other observations also suggest that the tyrosine phosphorylation of BRCA1 may relate to its functional state. A putative tyrosine phosphorylation site (amino acid residues 1555 ± 1563 in human BRCA1) is conserved among human, mouse and rat (Miki et al., 1994; Abel et al., 1995; Bennett et al., 1996) . This site is contained in the C-terminal region that is reported to have transcriptional activity (Chapman and Verma, 1996) . Tyrosine phosphorylation has been reported to
Blot: a b Figure 4 Regulation of tyrosine phosphorylation of BRCA1 is cell-cycle dependent. (a) NIH3T3 cells were enriched in G 1 /S or G 2 /M cell cycle stage with aphidicolin (5 mg/ml) or nocodazole (50 ng/ml) for 18 h before nuclear extracts were prepared. The change of tyrosine phosphorylation of BRCA1 during the cell cycle was examined by immunoblot analysis of the nuclear fractions similar to the procedure described in Figure 2 . The relative tyrosine phosphorylation level of p215, measured by densitometry scanning and normalized by the density of corresponding 579 bands, was 1 : 1.7 : 5.2 (control : aphidicolin : nocodazole). (b) A duplicate set of NIH3T3 cells were analysed for DNA content using propidium iodide staining. Histograms of cell cycle distribution were calculated from a sample of 10 000 events (Ormerod, 1994) play an important role in the regulation of activities of some transcriptional factors, such as the STAT proteins (Darnell et al., 1994) , the nuclear factor-1 like repressor BEF-1 (Reifel et al., 1994) , and the Hepatocyte nuclear factor 4 (HNF-4, Ktistaki et al., 1995) . Interestingly, a germline missense mutation (Thr?Ile) was previously detected at residue 1561 within the phosphotyrosine motif in a breast/ovarian cancer patient and was not seen in 240 control individuals (Durocher et al., 1996) . It is conceivable that speci®c mutations, by making the motif structurally less favorable for phosphorylation and driving the p215 BRCA1 into the hypophosphorylation form that we observed in the transformed cell, may in¯uence p215 BRCA1 function in breast and ovarian cancers. Another missense mutation was found in the phosphotyrosine motif from residue 823 to 831, although this site is not conserved in the mouse BRCA1 gene (Simard et al., 1994) .
The subcellular localization of the BRCA1 proteins is an interesting topic which may provide information about the regulation of BRCA1 functions. Unfortunately, there is no consensus on this issue. Although antibody cross-reactivities and certain technical treatments could account for some contradictory and confusing observations in this ®eld (Scully et al., 1996; Wilson et al., 1996) , splice variants may also complicate the situation. Recently, BRCA1 splice variants lacking exon 11 were identi®ed and had a predominant cytoplasmic localization, consistent with the fact that the nuclear localization signal (NLS) motifs are not carried by these variants Thakur et al., 1997) . The monoclonal and polyclonal antibodies used in our studies are generated for epitopes encoded by exon 11 and therefore are speci®c for the full length BRCA1 products. Our data indicate that the full-length endogenous BRCA1 polypeptides must move from the cytosol where it is made and thereafter resides predominantly in the nucleus regardless of cell type. This is consistent with other observations (Scully et al., 1996; Rao et al., 1996) . We have also noted that some neu receptor disabling antibodies induce a rapid accumulation of p215 BRCA1 in the nucleus (Zhang et al., in preparation) suggesting that translocation can be modulated and supports the notion that in some cases abnormal mislocated p215 BRCA1 polypeptides may be detected. BRCA1 mutations are generally not found in sporadic breast and ovarian cancers (Miki et al., 1994) . Our analysis of p215 BRCA1 suggests that alterations of p215 BRCA1 phosphorylation patterns might be investigated in breast cancers, in addition to genetic mutations of the BRCA1 gene. Although the direct demonstration of the membership of both p185 neu (and/ or EGFr) and BRCA1 in a common signaling pathway requires further investigation, our studies begin to de®ne interactions between these breast cancer gene products. Finally our studies suggest the possibility that modulating the p185/EGFr pathway may aect not only sporadic, but also heritable forms of breast cancers.
Materials and methods
Cell lines
The creation and properties of the murine ®broblast line NR6 and transfectants (Tneu, Tneu/T691, B104-1-1, B104/T691, and NE91) have been described previously (Qian et al., 1996) . These cell lines were maintained in Dulbecco's Modi®ed Eagle's medium (DMEM) containing 5% fetal bovine serum (FBS, Hyclone). Human breast cell line HBL100 and breast cancer cell lines, MCF7, T47D and SKBR3, were cultured in DMEM supplemented with 10% FBS.
Antibodies
A peptide corresponding to amino acids 903 to 919 of the human p215 BRCA1 (CEQKEENQGKNESNIKP) was synthesized. Blast (Altschul, et al., 1990) search of the sequence corresponding to this peptide veri®ed its speci®city to BRCA1 gene product. This peptide was coupled to KLH using a MBS protocol, was dialyzed extensively against phosphate-buered saline, then used to immunize rabbits (Cocalico Biologicals, Inc., Reamstown, PA). The Rabbit polyclonal antiserum was named 579. The production of monoclonal antibodies against peptide (CEQKEENQG-KNESNIKP) coupled to KLH was performed as described elsewhere (Kajino et al., in preparation and Drebin et al., 1985) . Each antibody was initially evaluated for binding to peptide in spot test assay (Data not shown, Davis et al., 1997) and then by immunoprecipitation of the p215 BRCA1 polypeptide from rodent and human cells. Monoclonal BRCA1 antibody Ab-1 was obtained from Oncogene Science, Inc. Polyclonal anti-BRCA1 antibodies C20 and M-20, as well as the monoclonal anti-pTyr antibody pY20 were purchased from Santa Cruz Biotechnology. Simultaneous use of other commercial antibodies as well as 579 veri®ed the polypeptides precipitated by Ki.8 and then blotted with pY20 were p215 BRCA1 .
In vitro translation BRCA1 cDNA was analysed using the TNT rabbit reticulocyte lysate coupled transcription/translation system (Promega). 1 mg of the construct containing the BRCA1 cDNA cloned downstream of T7 RNA polymerase promoter was used in a 50 ml translation mixture containing [ 35 S]-methionine according to the manufacturer's protocols. Translation mixture was pre-cleared with 1 mg of preimmune serum. Each 1/5 of reaction was used for immunoprecipitation. The immune complexes were precipitated with Protein A-Agarose (GIBCO/BRL), resolved on 7.5% SDS ± PAGE gel and exposed to Kodak X-ray ®lm.
Preparation of nuclear and cytoplasmic extracts
The nuclear and cytoplasmic extracts used in the Western immunoblot were prepared as described (Sadowski et al., 1993) , except that hypotonic buer containing 0.540 mM NaCl was used to dissolve the nuclear extracts.
Immunoprecipitation and Western blotting
Approximately 10 million cells were used for the immunoprecipitation of the p215 BRCA1 polypeptide (Wada et al., 1990) . For Western blotting, the primary antibodies were diluted by 1 : 5000. The antigen-antibody interaction was detected by ECL (Amersham) assay with 1 : 5000 diluted peroxidase-conjugated secondary antibodies (Boehringer Mannheim).
FACS analysis
To calibrate the cell cycle distribution, trypsinized cells (*5610 5 ) were ®xed in 70% ethanol, washed with PBS and resuspended in 1 ml PBS containing 140 mg/ml RNase A and 80 mg/ml propidium iodide for 30 min at 378C. Samples were analysed using a FACScan¯ow cytometer (Becton Dickinson).
